While Prax­is moves for­ward, Neu­ro­crine drops its es­sen­tial tremor drug

While Neu­ro­crine Bio­sciences con­tin­ues to grow the sales of its tar­dive dysk­i­ne­sia drug for pa­tients who ex­pe­ri­ence un­com­mon side ef­fects from men­tal health drugs, it hit a snag in its de­vel­op­ment of an es­sen­tial tremor drug.

In a Phase II study with 30 pa­tients, the can­di­date, a T-type cal­ci­um chan­nel block­er dubbed NBI-827104, did not meet its end­points, and Neu­ro­crine doesn’t plan to study the drug fur­ther for es­sen­tial tremor, CMO Eiry Roberts said dur­ing Neu­ro­crine’s Q2 in­vestor call.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.